WHO ICTRP trial
FDHT-PET to visualize the effect on the androgen receptor level by bicalutamide
NL-OMON47891 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON47891 |
|---|---|
| Public title | FDHT-PET to visualize the effect on the androgen receptor level by bicalutamide |
| Scientific title | FDHT-PET to visualize the effect on the androgen receptor level by bicalutamide - bicalutamide and FDHT PET in metastatic breast cancer patients |
| Primary sponsor | Universitair Medisch Centrum Groningen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | metastatic breast cancer;10006291;metastatic breast cancer |
| Interventions | All patients will receive a baseline FDHT-PET scan and start with bicalutamide treatment 150mg daily. During follow-up patients will receive one FDHT-PET scan after 4 weeks. Treatment with bicalutamide will continue until progression or… |
| Registration date | May 29, 2019 |
| Target size | 22 |
| Secondary IDs | 2015-001634-17;NL53358.042.15 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: